Application
Antibodies tested include p-PTEN (Ser 380/Thr 382/383): (A, B, C) and PTEN (N-19): (D, E, F).Application
Western blot analysis of PTEN phosphorylation in non-transfected 293T: (A), human PTEN transfected 293T: (B) and WI 38 (C) whole cell lysates.Application
Western blot analysis of phosphorylated PTEN expression in untreated (A) and Calyculin A-treated (B) HT29 whole cell lysates.Application
Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.| Product Name | p-PTEN Antibody (Ser 380/Thr 382/383) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | epitope corresponding to phosphorylated Ser 380/Thr 382/383 of PTEN of human origin |
| Modification | Phosphoralated |
| Modification Notes | As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10q23. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN gene, also designated MMAC1 (for mutated in multiple advanced cancers) and TEP1. This candidate tumor suppressor gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. PTEN has been associated with Cowden disease, an autosomal dominant cancer predisposition syndrome. The PTEN gene product is a putative protein tyrosine phosphatase that is localized to the cytoplasm, and it shares extensive homology with the cytoskeletal proteins tensin and auxilin. Gene transfer studies have indicated that the phosphatase domain of PTEN is essential for growth suppression of glioma cells. PTEN contains five major phosphorylation sites and these are all located in the C-terminal 50–amino acid tail region (Ser370, Ser380, Thr382, Thr383, and Ser385) and have been implicated in controlling PTEN activity. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBIPIFIHC |
| recommended for detection of Ser 380/Thr 382/383 phosphorylated PTEN of mouse, rat and human origin by WB, IP, IF and IHC(P): |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Alternative Names | epitope corresponding to phosphorylated Ser 380/Thr 382/383 of PTEN of human origin |
|---|---|
| Tissue Specificity | epitope corresponding to phosphorylated Ser 380/Thr 382/383 of PTEN of human origin |
| Entrez Gene | 5728 |
|---|
Application
Antibodies tested include p-PTEN (Ser 380/Thr 382/383): (A, B, C) and PTEN (N-19): (D, E, F).
Application
Western blot analysis of PTEN phosphorylation in non-transfected 293T: (A), human PTEN transfected 293T: (B) and WI 38 (C) whole cell lysates.
Application
Western blot analysis of phosphorylated PTEN expression in untreated (A) and Calyculin A-treated (B) HT29 whole cell lysates.
Application
Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.| Application Notes | recommended for detection of Ser 380/Thr 382/383 phosphorylated PTEN of mouse, rat and human origin by WB, IP, IF and IHC(P): |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
